Mathematical simulations predict that dapagliflozin slows cardiac remodeling by reducing preload on the heart and relieves congestion by clearing interstitial fluid without excessively reducing blood volume.
Does simulated dapagliflozin improve cardiac hemodynamics and relieve congestion in virtual patients with HF-rEF?
This mathematical modeling study provides a quantitative mechanistic explanation for the benefits of SGLT2 inhibitors in HF-rEF, suggesting they slow cardiac remodeling by reducing preload and relieve congestion by clearing interstitial fluid.
Congestive heart failure is characterized by suppressed cardiac output and arterial filling pressure, leading to renal retention of salt and water, contributing to further volume overload. Mathematical modeling provides a means to investigate the integrated function and dysfunction of heart and kidney in heart failure. This study updates our previously reported integrated model of cardiac and renal functions to account for the fluid exchange between the blood and interstitium across the capillary membrane, allowing the simulation of edema. A state of heart failure with reduced ejection fraction (HF-rEF) was then produced by altering cardiac parameters reflecting cardiac injury and cardiovascular disease, including heart contractility, myocyte hypertrophy, arterial stiffness, and systemic resistance. After matching baseline characteristics of the SOLVD clinical study, parameters governing rates of cardiac remodeling were calibrated to describe the progression of cardiac hemodynamic variables observed over one year in the placebo arm of the SOLVD clinical study. The model was then validated by reproducing improvements in cardiac function in the enalapril arm of SOLVD. The model was then applied to prospectively predict the response to the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin, which has been shown to reduce heart failure events in HF-rEF patients in the recent DAPAHF clinical trial by incompletely understood mechanisms. The simulations predict that dapagliflozin slows cardiac remodeling by reducing preload on the heart, and relieves congestion by clearing interstitial fluid without excessively reducing blood volume. This provides a quantitative mechanistic explanation for the observed benefits of SGLT2i in HF-rEF. The model also provides a tool for further investigation of heart failure drug therapies.
Yu et al. (Mon,) conducted a other in Heart failure with reduced ejection fraction (HF-rEF). Dapagliflozin vs. Placebo was evaluated on Left ventricular end-diastolic pressure and interstitial fluid volume. Mathematical simulations predict that dapagliflozin slows cardiac remodeling by reducing preload on the heart and relieves congestion by clearing interstitial fluid without excessively reducing blood volume.